Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 22:12:1461278.
doi: 10.3389/fcell.2024.1461278. eCollection 2024.

Unraveling the interplay: exploring signaling pathways in pancreatic cancer in the context of pancreatic embryogenesis

Affiliations
Review

Unraveling the interplay: exploring signaling pathways in pancreatic cancer in the context of pancreatic embryogenesis

Sashikanta Swain et al. Front Cell Dev Biol. .

Abstract

Pancreatic cancer continues to be a deadly disease because of its delayed diagnosis and aggressive tumor biology. Oncogenes and risk factors are being reported to influence the signaling pathways involved in pancreatic embryogenesis leading to pancreatic cancer genesis. Although studies using rodent models have yielded insightful information, the scarcity of human pancreatic tissue has made it difficult to comprehend how the human pancreas develops. Transcription factors like IPF1/PDX1, HLXB9, PBX1, MEIS, Islet-1, and signaling pathways, including Hedgehog, TGF-β, and Notch, are directing pancreatic organogenesis. Any derangements in the above pathways may lead to pancreatic cancer. TP53: and CDKN2A are tumor suppressor genes, and the mutations in TP53 and somatic loss of CDKN2A are the drivers of pancreatic cancer. This review clarifies the complex signaling mechanism involved in pancreatic cancer, the same signaling pathways in pancreas development, the current therapeutic approach targeting signaling molecules, and the mechanism of action of risk factors in promoting pancreatic cancer.

Keywords: embryogenesis; pancreatic cancer; signaling pathway; therapeutic approach; transcription factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Showing different signalling pathways involved in pancreatic development and carcinogenesis.

Similar articles

References

    1. Aashaq S., Batool A., Mir S. A., Beigh M. A., Andrabi K. I., Shah Z. A. (2022). TGF β signaling: a recap of SMAD independent and SMAD‐dependent pathways. J. Cell. physiology 237 (1), 59–85. 10.1002/jcp.30529 - DOI - PubMed
    1. Adamopoulos C., Cave D. D., Papavassiliou A. G. (2024). Inhibition of the RAF/MEK/ERK signaling cascade in pancreatic cancer: recent advances and future perspectives. Int. J. Mol. Sci. 25 (3), 1631. 10.3390/ijms25031631 - DOI - PMC - PubMed
    1. Ahn D. H., Ramanathan R. K., Bekaii-Saab T. (2018). Emerging therapies and future directions in targeting the tumor stroma and immune system in the treatment of pancreatic adenocarcinoma. Cancers (Basel) 10, 193. 10.3390/cancers10060193 - DOI - PMC - PubMed
    1. Amthor H., Nicholas G., McKinnell I., Kemp C. F., Sharma M., Kambadur R., et al. (2004). Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Dev. Biol. 270 (1), 19–30. 10.1016/j.ydbio.2004.01.046 - DOI - PubMed
    1. Austen J., Bronte E. (2023). Oncogenic signaling pathways in carcinogenesis. J. Carcinog. 22 (1). 10.4103/jcar.jcar_22_01_16 - DOI

LinkOut - more resources